Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03984383
NCT03984383WithdrawnNot Applicable

Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells

University Hospital, Lille1 site in 1 countryStarted: November 8, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Sponsor
Locations
1
Primary Endpoint
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants.

For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells.

Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery.

Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age > 18 years
  • •signed consent
  • •Pregnant woman for umbilical cord-derive-endothelial cells

Exclusion Criteria

  • •Age < 18 years
  • •Refusal to participate to the study
  • •Endothelial cord-drived endothelial cells :
  • •significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.)
  • •infection for HIV, VHB, VHC
  • •unknown status for HIV, VHB, VHC the day of the childbirth.

Outcomes

Primary Outcomes

change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.

Time Frame: change from Baseline at 48 hours after stimulation

Secondary Outcomes

  • change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours after stimulation)
  • change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)
  • change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.(change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation)

Investigators

Sponsor
University Hospital, Lille
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic TreatmentEndothelial DysfunctionInflammatory Disease ActivityRheumatoid ArthritisPsoriatic ArthritisAnkylosing Spondylitis
NCT00902005Revmatismesykehuset AS145
Unknown
Not Applicable
Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea (OSA) and Effect of 6-month CPAP TreatmentSleep Apnea, ObstructiveContinuous Positive Airway PressureEndotheliumInflammationVascular Function
NCT01312168National Taiwan University Hospital150
Recruiting
Not Applicable
Characterisation of Endothelial Cells in Different Inflammatory PathologiesVasoplegiaSepsis
NCT06613256Royal Surrey County Hospital NHS Foundation Trust105
Terminated
Not Applicable
Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus PlaceboSmoking
NCT00673595Mayo Clinic19
Completed
Not Applicable
Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program ParticipantsCoronary Artery Disease (CAD)
NCT00308633National Heart, Lung, and Blood Institute (NHLBI)55